Maintenance therapy with ICIs (atezolizumab or durvalumab) is already established in extensive stage small-cell lung cancer, but lurbinectedin enters the chat with a recent FDA approval. Next up - tarlatamab?
IMforte (maintenance lurbinectedin + atezolizumab): https://doi.org/10.1016/S0140-6736(25)01011-6
DeLLphi-303 (phase 1b maintenance tarlatamab + ICI ... Show More
Sep 25
SC Pembro, Biotin, 5-yr POLARIX data
The long awaited subcutaneous formulation of pembrolizumab is not FDA-approved. We discuss its administration and toxicity & PK differences vs. IV use. Biotin supplementation can interfere with lots of labs cancer patients get routinely - Who knew? (Ahem, not me.) Link: https://d ... Show More
18 m
Jun 2021
Review Series on Platelets and Cancer
Platelets are critical for hemostasis and thrombosis, but recent research highlights their role in many other processes, including inflammation, wound healing, and lymphangiogenesis. In this episode, Drs. José López, Elisabeth Battinelli, Craig Williams, and Owen McCarty discuss ... Show More
35m 27s
Sep 8
Marsquakes, Vaccine Politics and Mammoth Microbiomes
This week’s roundup dives into Mars’s lumpy mantle, a nasal spray that may help prevent COVID and the growing confusion around vaccine access in the U.S. Plus, researchers link phone use while on the toilet to hemorrhoid risk, uncover ancient mammoth microbiomes and explain why s ... Show More
9m 45s
Aug 14
11: Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma
The latest Oncology Decoded discussion with Manojkumar Bupathi, MD, MS, executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and ... Show More
41m 45s